Skip to main content

Advertisement

ADVERTISEMENT

CR-33

Effectiveness of a native Type I Collagen matrix plus polyhexamethylene biguanide (PHMB) antimicrobial in the treatment of pressure injuries in a real-world setting

Michael Menack, Kerry Thibodeaux, MD – Medical Director, The Wound Treatment Center, Opelousas General Health System, Surgery, Opelousas General Health System; Carlos Trabanco, MD – Medical Director, West Gables Rehabilitation Hospital Wound Care Center, General Surgery, West Gables Rehabilitation Hospital Wound Care Center, Miami, FL; Michael Sabolinski, MD – Managing Member and CMO*; Corresponding author, Medical, Sabolinski LLC
Objective: To analyze the subgroup of Pressure Injuries (PRIs) in the 28 site, prospective, non-interventional, PCMP registry (RESPOND)(a) that evaluated the real-world effectiveness of PCMP(b) (native Type I Collagen matrix plus PHMB; polyhexamethylene biguanide antimicrobial) on chronic and acute wounds. Methods: PCMP is intended for the management of partial and full thickness wounds (except 3rd degree burns) and as an effective barrier to reduce microbes penetrating through the dressing. All patients (n=307) in RESPOND received PCMP. Male and female patients, ≥18 years with cutaneous wounds not including third degree burns were eligible for participation. Wounds ≥0.2 and

Sponsor

Sponsor name
This study was funded by Organogenesis, Inc., Canton, MA.

Product Information

PuraPly AM®, Organogenesis Inc, Canton, MA

Trademark

(a) RESPOND Registry; Real-World Effectiveness Study of PuraPly AM® on Wounds (b) PuraPly AM®, Organogenesis Inc, Canton, MA

Advertisement

Advertisement

Advertisement